Table A5. Full outputs of all analysis models presented in main paper (for stage III/IV vs I/II comparisons).

	Complete case analysis			Multiple imputation				Missing stage=stage III/IV
	OR	95% LCI	95% UCI	OR	95% LCI	95% UCI	FMI	OR	95% LCI	95% UCI
(a) Breast cancer, stage III/IV vs stage I–II
15–39	1.15	0.89	1.48	1.13	0.88	1.46	0.062	1.08	0.87	1.34
40–44	1.02	0.81	1.28	1.01	0.80	1.27	0.069	0.85	0.70	1.05
45–49	0.91	0.74	1.14	0.91	0.73	1.13	0.088	0.85	0.70	1.02
50–54	0.92	0.74	1.14	0.90	0.72	1.11	0.066	0.93	0.78	1.11
55–59	0.90	0.72	1.12	0.88	0.71	1.09	0.058	0.81	0.67	0.98
60–64	0.91	0.74	1.12	0.89	0.73	1.10	0.076	0.86	0.72	1.02
65–69	Ref.			Ref.				Ref.
70–74	1.21	0.98	1.49	1.22	0.99	1.50	0.064	1.08	0.90	1.29
75–79	1.46	1.20	1.78	1.50	1.23	1.82	0.062	1.30	1.09	1.54
80–84	1.68	1.37	2.07	1.75	1.43	2.15	0.115	1.77	1.49	2.10
⩾85	1.78	1.45	2.18	1.86	1.52	2.27	0.128	2.21	1.87	2.62
Most affluent	Ref.			Ref.				Ref.
2	1.16	1.02	1.32	1.20	1.05	1.36	0.107	1.12	1.00	1.25
3	1.12	0.98	1.28	1.16	1.02	1.32	0.091	1.07	0.95	1.19
4	1.29	1.12	1.49	1.32	1.15	1.52	0.116	1.21	1.07	1.36
Deprived	1.23	1.00	1.52	1.27	1.03	1.57	0.149	1.07	0.89	1.29
Infiltrating ductal carcinoma	Ref.			Ref.				Ref.
Lobular carcinoma	1.59	1.39	1.81	1.62	1.42	1.84	0.061	1.54	1.38	1.73
Mixed ductal lobular	1.09	0.90	1.32	1.10	0.91	1.33	0.051	0.97	0.82	1.15
Other adenocarcinoma	0.99	0.79	1.25	0.98	0.78	1.23	0.058	0.99	0.82	1.20
Other specified carcinoma	0.58	0.26	1.26	0.58	0.27	1.27	0.118	0.90	0.52	1.54
Other unspecified	3.90	3.26	4.66	4.01	3.37	4.77	0.254	4.57	3.93	5.32
Specified not carcinoma	3.57	0.28	46.04	1.78	0.14	22.25	0.870	81.48	19.36	342.93
Screening detection status- no	Ref.
Screening detection status-yes	0.26	0.22	0.31	0.27	0.22	0.32	0.030	0.20	0.17	0.24
(b) Lung cancer, odds ratios of stage III/IV vs stage I/II
Women	Ref.			Ref.				Ref.
Men	1.14	1.03	1.25	1.13	1.03	1.25	0.170	1.15	1.05	1.27
15–49	1.33	0.93	1.90	1.23	0.86	1.75	0.197	1.31
50–54	1.00	0.74	1.35	0.96	0.71	1.30	0.157	0.95	0.93	1.84
55–59	1.26	0.99	1.61	1.22	0.96	1.55	0.119	1.23	0.71	1.27
60–64	0.96	0.79	1.18	0.95	0.78	1.16	0.150	0.95	0.97	1.56
65–69	Ref.			Ref.					0.78	1.15
70–74	0.82	0.68	0.97	0.80	0.68	0.96	0.109	0.82	0.69	0.98
75–79	0.74	0.62	0.88	0.72	0.60	0.86	0.171	0.75	0.64	0.89
80–84	0.73	0.61	0.88	0.73	0.61	0.87	0.16	0.78	0.65	0.93
⩾85	0.66	0.54	0.81	0.68	0.55	0.83	0.23	0.76	0.62	0.92
Most affluent	Ref.			Ref.				Ref.
2	0.94	0.81	1.09	0.97	0.84	1.12	0.138	0.95	0.82	1.10
3	0.97	0.83	1.12	1.01	0.87	1.17	0.184	0.97	0.84	1.12
4	0.98	0.84	1.14	1.04	0.89	1.21	0.209	0.99	0.86	1.15
Deprived	0.81	0.66	0.99	0.91	0.75	1.10	0.186	0.82	0.67	0.99
Adenocarcinoma	Ref.			Ref.				Ref.
Squamous cell carcinoma	0.91	0.79	1.05	0.89	0.77	1.02	0.116	0.83	0.72	0.95
Other non-small cell types	2.07	1.77	2.42	1.97	1.70	2.29	0.099	1.87	1.61	2.18
Small cell carcinoma	4.06	3.23	5.12	3.90	3.10	4.92	0.207	3.94	3.14	4.94
Large cell carcinoma	1.51	0.97	2.36	1.44	0.93	2.22	0.065	1.29	0.83	1.99
Carcinoida	0.02	0.00	0.18	0.02	0.00	0.15	0.764	1.53	0.87	2.70
Specified othera	0.41	0.03	6.63	0.74	0.06	9.27	0.627	2.30	0.29	18.35
Unspecified other	1.94	1.67	2.24	1.85	1.59	2.15	0.289	2.07	1.80	2.37

Abbreviations: FMI=fraction of missing information (for each respective variable category, it denotes the proportion of the estimation that used imputed missing information); LCI=lower confidence interval; OR=odds ratio; Ref=reference; UCI=upper confidence interval.

^aFor these two groups, large differences are apparent between the analysis under the missing stage=stage IV analysis and either complete case analysis or multiple imputation. Both these groups were small and had a particularly small proportion of patients with observed stage (<20%), most of whom were in stage I/II. The above indicate that the missing stage=stage IV assumption for patients with missing stage in these two groups is unlikely to be reasonable; we nevertheless present findings for consistency.